Skip to content

Geron GERN Non-cash interest expense on liabilities for sales of future royalties

Non-cash interest expense on liabilities for sales of future royalties at other companies

Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$21M+50.0%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$21M+50.0%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$65.7M+32.3%
Arrowhead Research logo
Arrowhead ResearchARWR
$8.83M+60.6%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$13.29M-1.6%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$7.94M+59.7%

Other financials

Income statement

See full
Revenue$51.8M+30.9%
Operating income$158.0K+101%
Net income-$3.6M+81.6%
EPS (diluted)-$0.01+66.7%

Balance sheet

See full
Cash & equivalents$48.7M-12.2%
Total debt$134.0M+10.0%
Total equity$229.1M-14.6%
Total assets$534.1M-5.0%

Cash flow

See full
Operating cash flow-$62.9M-31.1%
CapEx$206.0K+2.0%
Free cash flow-$43.8M-6.8%

Valuation

See full
Market cap$888.51M-8.6%
Enterprise value$973.78M-6.2%
P/S4.7×-174×

Profitability

See full
Operating margin-705.5%-351pp
Net margin-682.5%-339pp
FCF margin-734.4%-365pp

Returns & leverage

See full
Return on equity-27.1%-7.8pp
Debt / equity0.6×+0.1×
Current ratio6.8×-1.1×

Where this comes from

Reported directly by Geron in its filing.

Tagged under the XBRL concept gern:NoncashInterestExpenseOnLiabilitiesForSalesOfFutureRoyalties.

The official record: Geron’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Geron's non-cash interest expense on liabilities for sales of future royalties.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Geron's non-cash interest expense on liabilities for sales of future royalties?
Geron (GERN) reported non-cash interest expense on liabilities for sales of future royalties of $3.91M in Q1 2026.
How has Geron's non-cash interest expense on liabilities for sales of future royalties changed year-over-year?
Geron's non-cash interest expense on liabilities for sales of future royalties decreased by 18.5% year-over-year, from $4.8M to $3.91M.
What does non-cash interest expense on liabilities for sales of future royalties mean?
This represents the non-cash interest expense accrued on financial obligations related to the sale of future royalty streams. It reflects the financing cost associated with monetizing future revenue rights upfront. This metric is critical for assessing the true cost of capital for companies that use royalty-backed financing to fund research and development.